Lilly Making First Milestone Payment in $1.9B Collaboration with AC Immune

GEN | September 20, 2019

Lilly Making First Milestone Payment in $1.9B Collaboration with AC Immune
Eli Lilly will pay AC Immune CHF 30 million ($30.2 million) in the first milestone payment tied to the companies’ CHF 1.89 billion ($1.9 billion) collaboration launched in December to develop new treatments for Alzheimer’s disease and other neurodegenerative disorders, the Swiss biotech said today. AC Immune said it will receive the milestone payment on or before October 7, 2019, in “a recognition of progress in the collaboration between the two companies”—namely the launch in July of a Phase I trial of ACI-3024, the company’s lead tau aggregation inhibitor small molecule candidate. The Phase I trial is designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ACI-3024 in healthy volunteers, AC Immune said, through a randomized, placebo controlled, double blind, sequential single and multiple ascending dose study with open label food effect and pharmacodynamics assessment arms. “The start of the ACI-3024 Phase 1 study, represents an important advancement in the broader effort we are making and further expands our robust clinical pipeline to address neurodegenerative diseases, in particular for therapeutics and diagnostics targeting Tau,” AC Immune CEO Prof. Andrea Pfeifer said in a statement.

Spotlight

Over the last thirty years the number of new antibiotic approvals has dropped. According to the Pew Institute, only two antibiotic products were approved by the US Food and Drug Administration in 2015. Many of the products approved in recent years are second, third or fourth generation antibiotics, meaning they are follow-up compounds, without a novel mechanism of action.

Related News

InDex Pharmaceuticals to present the successful results of the CONDUCT study at two leading medical conferences

Prnewswire | August 24, 2020

We are very pleased that the abstract with the CONDUCT study results has been selected for oral presentation at both the UEGW and the ACG Annual Scientific Meeting", says Peter Zerhouni, CEO of InDex Pharmaceuticals. "These events are great opportunities for us to further reach the international scientific community with the successful results." UEGW is the largest scientific meeting for gastroenterologists in Europe and is this year held virtually October 11-13. The CONDUCT study will be presented on October 12 during the session "IBD: Clinical trials III" which starts at 16:30 CET. The abstract (OP117) is titled "COBITOLIMOD FOR MODERATE-TO-SEVERE LEFT-SIDED ULCERATIVE COLITIS (CONDUCT): A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL".

Read More

No single manufacturer can meet coronavirus vaccine global demand, says Moderna CEO

Cnbc | May 13, 2020

Moderna CEO Stephane Bancel said Tuesday that he hopes many coronavirus vaccines from multiple manufacturers will be approved to enter the market, because no single manufacturer can meet global demand. Regeneron CEO Leonard Schleifer, whose company is developing an antibody drug against Covid-19, told CNBC that the problem isn’t with the physical distribution of a potential coronavirus drug but rather with the ability to meet demand. Experimental vaccines will need to be mass produced and administered to more than 7.6 billion people around the world. Moderna CEO Stephane Bancel said he hopes U.S. and international regulators approve several coronavirus vaccines from multiple companies, because no single manufacturer will be able to meet global demand. “The odds that every program works are really low, obviously, but I really hope we have three, four, five vaccines, because no manufacturer can make enough doses for the planet,” Bancel said during CNBC’s Healthy Returns Virtual Summit. Moderna has developed one of the leading coronavirus vaccine candidates in the world. The company is currently wrapping up phase one human trials on it in Seattle and is about to start phase 2 two trials, it announced last week. If it’s effective and safe to use, it could be ready for market in early 2021, the company said. Bancel said Moderna is working closely with Dr. Anthony Fauci’s team at the National Institute of Allergy and Infectious Diseases as well as the Centers for Disease Control and Prevention to determine the best plan to distribute the vaccine, which could be ready in 12 to 18 months within the U.S. On Tuesday, the U.S. Food and Drug Administration granted “fast track” designation to Moderna’s coronavirus vaccine, a move that speeds up the regulatory review process. Other companies racing to develop a vaccine include Pfizer and Inovio, which have already started clinical trials. On Thursday, Moderna said it will soon begin phase two trials with 600 participants and is finalizing plans for a phase three trial as early as this summer. Read More: U.S. STATES BUILD STOCKPILES OF MALARIA DRUG TOUTED BY TRUMP Even as the company ramps up its manufacturing capacity so it can rapidly distribute doses if the vaccine proves effective against the virus and safe for humans, it won’t immediately have enough for everyone, Bancel told CNBC on Friday. Regeneron CEO Leonard Schleifer, whose company is developing an antibody drug against Covid-19 with plans to enter human trials in June, told CNBC that the problem isn’t with the physical distribution of a potential coronavirus drug, which could be made available by major retail chains, but rather with the ability to meet demand. There are more than 7.6 billion people in the world, and it could take years to vaccinate enough people to achieve so-called herd immunity. “The physical distribution aspect I think is more than adequate. I do think there will be a capacity issue,” Schleifer said. Schleifer said multiple companies will need to succeed in the development of their coronavirus therapeutics because “the demand will far exceed the capacity.” We simply cannot do this on an auction basis, whatever state and local area or company wants to pay the highest amount to get access, we can’t do it that way, it’s the role of federal, state and other global governments to ensure the drugs are distributed equitably. -Regeneron CEO Leonard Schleifer He said the company is trying to get its drug into patients within five months, which would be the fastest it’s ever done so. It took the company nine months to develop an antibody drug for Ebola, he said. During a congressional hearing Tuesday, Fauci told lawmakers, “There’s no guarantee that the vaccine is actually going to be effective.” There are currently no proven treatments or vaccines against Covid-19. “One of the big unknowns is, will it be effective? Given the way the body responds to viruses of this type, I’m cautiously optimistic that we will with one of the candidates get an efficacy signal,” Fauci said. Read More: COVID-19 ANTI-VIRAL DRUG REMDESIVIR EFFECTIVE ON MONKEYS AND PEOPLE

Read More

RESEARCH

Thermo Fisher sketches out Carlsbad plasmid DNA plant as German cell and gene therapy facility preps for opening

Thermo Fisher | December 23, 2020

Thermo Fisher Scientific is shoring up production of cell and quality treatments on the two sides of the lake, a move it expectations will support the advancement of COVID-19 medications and antibodies—and guarantee supplies are set up should they get by with controllers. The New Jersey contract producer is spreading out another plasmid DNA fabricating office at its Carlsbad, California, grounds, intending to help its phone and quality treatment contributions against the setting of a worldwide plasmid market where request has immediately dominated supply, the organization said. That is on top of plans for another cryocenter in Germany. That webpage, one of two new German offices set to come online in the following not many weeks, will offer virus chain support for clinical preliminaries of cell and quality treatments, including COVID-19 immunization hopefuls, in Europe and past. The 67,000-square-foot Carlsbad office will add exactly 150 positions throughout the following a year, with development fixed to enclose by the principal half of 2021, Thermo Fisher said. The site will support clinical and business yield of plasmid DNA used to create and deliver cell and quality treatments for disease, just as mRNA immunizations. It will likewise be prepared to produce huge scope plasmid DNA as an essential medication substance for DNA treatments, the organization said. The office will be kitted out with single-utilize hardware equipped for taking care of undertakings up to 1,000 liters and will flaunt computerized network and information visibility to smooth activities and make preparing representatives simpler, Thermo Fisher said. Thermo Fisher is no more abnormal to the field, with a phone and quality treatment impression in Massachusetts and Florida, in addition to a recently stamped cell treatment producing plant in Princeton, New Jersey—however it calculates the extended business and supply chain administrations at its Carlsbad site will smooth the wrinkles in the current plasmid market. "The competition to grow new groundbreaking cell and quality treatments and antibodies is outperforming supply of business quality plasmid DNA that can be created at scale," Mike Shafer, SVP and leader of pharma administrations at Thermo Fisher, said in a delivery. "Our new cutting edge site won't just handle the supply bottleneck for our clients yet in addition particularly positions us to convey powerful, start to finish cell and quality treatment capacities."

Read More

Spotlight

Over the last thirty years the number of new antibiotic approvals has dropped. According to the Pew Institute, only two antibiotic products were approved by the US Food and Drug Administration in 2015. Many of the products approved in recent years are second, third or fourth generation antibiotics, meaning they are follow-up compounds, without a novel mechanism of action.